Anaplastic Lymphoma Kinase Inhibitors Market Insights, Global Outlook and Forecast 2022-2028
Anaplastic Lymphoma Kinase Inhibitors Market Insights, Global Outlook and Forecast 2022-2028
Discover the latest insights into the booming Anaplastic Lymphoma Kinase Inhibitors Market. This report analyzes market size, growth trends (CAGR ), key players, and regional performance, offering valuable data for investors and industry professionals. Explore market drivers, restraints, and future projections for -.
Exclusive deal : 20% Instant discount on Direct purchases! Don't wait—claim your discount today!
ALK inhibitors are potential anti-cancer drugs that act on tumours with variations of anaplastic lymphoma kinase (ALK) such as an EML4-ALK translocation.[
The latest research study released by Market IntelliX evaluates market size and forecasts of Anaplastic Lymphoma Kinase Inhibitors in global, including the following market information:
Global Anaplastic Lymphoma Kinase Inhibitors Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Anaplastic Lymphoma Kinase Inhibitors Market Sales, 2017-2022, 2023-2028, (MT)
Global top five Anaplastic Lymphoma Kinase Inhibitors companies in 2021 (%)
The global Anaplastic Lymphoma Kinase Inhibitors market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Crizotinib Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Anaplastic Lymphoma Kinase Inhibitors include Betta Pharmaceutcials Co., Ltd., Crtierium, Inc., F.Hoffman-La Roche Ltd., Helsinn Therapeutics, Novartis AG., Oncoethix GmbH, Pfizer, Inc., Takeda Pharmaceutical Co., Ltd. and Xcovery Holding Company, LLC and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MI has surveyed the Anaplastic Lymphoma Kinase Inhibitors manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Market Segmentations:
Global Anaplastic Lymphoma Kinase Inhibitors Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (MT)
Global Anaplastic Lymphoma Kinase Inhibitors Market Segment Percentages, by Type, 2021 (%)
Crizotinib
Ceritinib
Alectinib Hydrochloride
Global Anaplastic Lymphoma Kinase Inhibitors Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (MT)
Global Anaplastic Lymphoma Kinase Inhibitors Market Segment Percentages, by Application, 2021 (%)
NSCLC
Breast Cancer
Colorectal Cancer
Neuroblastoma
Ovarian Cancer
Others
Global Anaplastic Lymphoma Kinase Inhibitors Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (MT)
Global Anaplastic Lymphoma Kinase Inhibitors Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Anaplastic Lymphoma Kinase Inhibitors revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Anaplastic Lymphoma Kinase Inhibitors revenues share in global market, 2021 (%)
Key companies Anaplastic Lymphoma Kinase Inhibitors sales in global market, 2017-2022 (Estimated), (MT)
Key companies Anaplastic Lymphoma Kinase Inhibitors sales share in global market, 2021 (%)
The report presents profiles of competitors in the market, Some of the prominent key players covered:
Betta Pharmaceutcials Co., Ltd.
Crtierium, Inc.
F.Hoffman-La Roche Ltd.
Helsinn Therapeutics
Novartis AG.
Oncoethix GmbH
Pfizer, Inc.
Takeda Pharmaceutical Co., Ltd.
Xcovery Holding Company, LLC
Tesaro, Inc.
Key Takeaways from this Report
Evaluate market potential through analyzing growth rates (CAGR %), Volume (Units) and Value ($M) data given at country level – for product types, end use applications and by different industry verticals.
Understand the different dynamics influencing the market – key driving factors, challenges and hidden opportunities.
Get in-depth insights on your competitor performance – market shares, strategies, financial benchmarking, product benchmarking, SWOT and more.
Analyze the sales and distribution channels across key geographies to improve top-line revenues.
Understand the industry supply chain with a deep-dive on the value augmentation at each step, in order to optimize value and bring efficiencies in your processes.
Get a quick outlook on the market entropy – M&A’s, deals, partnerships, product launches of all key players for the past 4 years.
Evaluate the supply-demand gaps, import-export statistics and regulatory landscape for more than top 20 countries globally for the market.
1 Introduction to Research & Analysis Reports
1.1 Anaplastic Lymphoma Kinase Inhibitors Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Anaplastic Lymphoma Kinase Inhibitors Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Anaplastic Lymphoma Kinase Inhibitors Overall Market Size
2.1 Global Anaplastic Lymphoma Kinase Inhibitors Market Size: 2021 VS 2028
2.2 Global Anaplastic Lymphoma Kinase Inhibitors Revenue, Prospects & Forecasts: 2017-2028
2.3 Global Anaplastic Lymphoma Kinase Inhibitors Sales: 2017-2028
3 Company Landscape
3.1 Top Anaplastic Lymphoma Kinase Inhibitors Players in Global Market
3.2 Top Global Anaplastic Lymphoma Kinase Inhibitors Companies Ranked by Revenue
3.3 Global Anaplastic Lymphoma Kinase Inhibitors Revenue by Companies
3.4 Global Anaplastic Lymphoma Kinase Inhibitors Sales by Companies
3.5 Global Anaplastic Lymphoma Kinase Inhibitors Price by Manufacturer (2017-2022)
3.6 Top 3 and Top 5 Anaplastic Lymphoma Kinase Inhibitors Companies in Global Market, by Revenue in 2021
3.7 Global Manufacturers Anaplastic Lymphoma Kinase Inhibitors Product Type
3.8 Tier 1, Tier 2 and Tier 3 Anaplastic Lymphoma Kinase Inhibitors Players in Global Market
3.8.1 List of Global Tier 1 Anaplastic Lymphoma Kinase Inhibitors Companies
3.8.2 List of Global Tier 2 and Tier 3 Anaplastic Lymphoma Kinase Inhibitors Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Anaplastic Lymphoma Kinase Inhibitors Market Size Markets, 2021 & 2028
4.1.2 Crizotinib
4.1.3 Ceritinib
4.1.4 Alectinib Hydrochloride
4.2 By Type - Global Anaplastic Lymphoma Kinase Inhibitors Revenue & Forecasts
4.2.1 By Type - Global Anaplastic Lymphoma Kinase Inhibitors Revenue, 2017-2022
4.2.2 By Type - Global Anaplastic Lymphoma Kinase Inhibitors Revenue, 2023-2028
4.2.3 By Type - Global Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share, 2017-2028
4.3 By Type - Global Anaplastic Lymphoma Kinase Inhibitors Sales & Forecasts
4.3.1 By Type - Global Anaplastic Lymphoma Kinase Inhibitors Sales, 2017-2022
4.3.2 By Type - Global Anaplastic Lymphoma Kinase Inhibitors Sales, 2023-2028
4.3.3 By Type - Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share, 2017-2028
4.4 By Type - Global Anaplastic Lymphoma Kinase Inhibitors Price (Manufacturers Selling Prices), 2017-2028
5 Sights By Application
5.1 Overview
5.1.1 By Application - Global Anaplastic Lymphoma Kinase Inhibitors Market Size, 2021 & 2028
5.1.2 NSCLC
5.1.3 Breast Cancer
5.1.4 Colorectal Cancer
5.1.5 Neuroblastoma
5.1.6 Ovarian Cancer
5.1.7 Others
5.2 By Application - Global Anaplastic Lymphoma Kinase Inhibitors Revenue & Forecasts
5.2.1 By Application - Global Anaplastic Lymphoma Kinase Inhibitors Revenue, 2017-2022
5.2.2 By Application - Global Anaplastic Lymphoma Kinase Inhibitors Revenue, 2023-2028
5.2.3 By Application - Global Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share, 2017-2028
5.3 By Application - Global Anaplastic Lymphoma Kinase Inhibitors Sales & Forecasts
5.3.1 By Application - Global Anaplastic Lymphoma Kinase Inhibitors Sales, 2017-2022
5.3.2 By Application - Global Anaplastic Lymphoma Kinase Inhibitors Sales, 2023-2028
5.3.3 By Application - Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share, 2017-2028
5.4 By Application - Global Anaplastic Lymphoma Kinase Inhibitors Price (Manufacturers Selling Prices), 2017-2028
6 Sights by Region
6.1 By Region - Global Anaplastic Lymphoma Kinase Inhibitors Market Size, 2021 & 2028
6.2 By Region - Global Anaplastic Lymphoma Kinase Inhibitors Revenue & Forecasts
6.2.1 By Region - Global Anaplastic Lymphoma Kinase Inhibitors Revenue, 2017-2022
6.2.2 By Region - Global Anaplastic Lymphoma Kinase Inhibitors Revenue, 2023-2028
6.2.3 By Region - Global Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share, 2017-2028
6.3 By Region - Global Anaplastic Lymphoma Kinase Inhibitors Sales & Forecasts
6.3.1 By Region - Global Anaplastic Lymphoma Kinase Inhibitors Sales, 2017-2022
6.3.2 By Region - Global Anaplastic Lymphoma Kinase Inhibitors Sales, 2023-2028
6.3.3 By Region - Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share, 2017-2028
6.4 North America
6.4.1 By Country - North America Anaplastic Lymphoma Kinase Inhibitors Revenue, 2017-2028
6.4.2 By Country - North America Anaplastic Lymphoma Kinase Inhibitors Sales, 2017-2028
6.4.3 US Anaplastic Lymphoma Kinase Inhibitors Market Size, 2017-2028
6.4.4 Canada Anaplastic Lymphoma Kinase Inhibitors Market Size, 2017-2028
6.4.5 Mexico Anaplastic Lymphoma Kinase Inhibitors Market Size, 2017-2028
6.5 Europe
6.5.1 By Country - Europe Anaplastic Lymphoma Kinase Inhibitors Revenue, 2017-2028
6.5.2 By Country - Europe Anaplastic Lymphoma Kinase Inhibitors Sales, 2017-2028
6.5.3 Germany Anaplastic Lymphoma Kinase Inhibitors Market Size, 2017-2028
6.5.4 France Anaplastic Lymphoma Kinase Inhibitors Market Size, 2017-2028
6.5.5 U.K. Anaplastic Lymphoma Kinase Inhibitors Market Size, 2017-2028
6.5.6 Italy Anaplastic Lymphoma Kinase Inhibitors Market Size, 2017-2028
6.5.7 Russia Anaplastic Lymphoma Kinase Inhibitors Market Size, 2017-2028
6.5.8 Nordic Countries Anaplastic Lymphoma Kinase Inhibitors Market Size, 2017-2028
6.5.9 Benelux Anaplastic Lymphoma Kinase Inhibitors Market Size, 2017-2028
6.6 Asia
6.6.1 By Region - Asia Anaplastic Lymphoma Kinase Inhibitors Revenue, 2017-2028
6.6.2 By Region - Asia Anaplastic Lymphoma Kinase Inhibitors Sales, 2017-2028
6.6.3 China Anaplastic Lymphoma Kinase Inhibitors Market Size, 2017-2028
6.6.4 Japan Anaplastic Lymphoma Kinase Inhibitors Market Size, 2017-2028
6.6.5 South Korea Anaplastic Lymphoma Kinase Inhibitors Market Size, 2017-2028
6.6.6 Southeast Asia Anaplastic Lymphoma Kinase Inhibitors Market Size, 2017-2028
6.6.7 India Anaplastic Lymphoma Kinase Inhibitors Market Size, 2017-2028
6.7 South America
6.7.1 By Country - South America Anaplastic Lymphoma Kinase Inhibitors Revenue, 2017-2028
6.7.2 By Country - South America Anaplastic Lymphoma Kinase Inhibitors Sales, 2017-2028
6.7.3 Brazil Anaplastic Lymphoma Kinase Inhibitors Market Size, 2017-2028
6.7.4 Argentina Anaplastic Lymphoma Kinase Inhibitors Market Size, 2017-2028
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Anaplastic Lymphoma Kinase Inhibitors Revenue, 2017-2028
6.8.2 By Country - Middle East & Africa Anaplastic Lymphoma Kinase Inhibitors Sales, 2017-2028
6.8.3 Turkey Anaplastic Lymphoma Kinase Inhibitors Market Size, 2017-2028
6.8.4 Israel Anaplastic Lymphoma Kinase Inhibitors Market Size, 2017-2028
6.8.5 Saudi Arabia Anaplastic Lymphoma Kinase Inhibitors Market Size, 2017-2028
6.8.6 UAE Anaplastic Lymphoma Kinase Inhibitors Market Size, 2017-2028
7 Manufacturers & Brands Profiles
7.1 Betta Pharmaceutcials Co., Ltd.
7.1.1 Betta Pharmaceutcials Co., Ltd. Corporate Summary
7.1.2 Betta Pharmaceutcials Co., Ltd. Business Overview
7.1.3 Betta Pharmaceutcials Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Major Product Offerings
7.1.4 Betta Pharmaceutcials Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Sales and Revenue in Global (2017-2022)
7.1.5 Betta Pharmaceutcials Co., Ltd. Key News
7.2 Crtierium, Inc.
7.2.1 Crtierium, Inc. Corporate Summary
7.2.2 Crtierium, Inc. Business Overview
7.2.3 Crtierium, Inc. Anaplastic Lymphoma Kinase Inhibitors Major Product Offerings
7.2.4 Crtierium, Inc. Anaplastic Lymphoma Kinase Inhibitors Sales and Revenue in Global (2017-2022)
7.2.5 Crtierium, Inc. Key News
7.3 F.Hoffman-La Roche Ltd.
7.3.1 F.Hoffman-La Roche Ltd. Corporate Summary
7.3.2 F.Hoffman-La Roche Ltd. Business Overview
7.3.3 F.Hoffman-La Roche Ltd. Anaplastic Lymphoma Kinase Inhibitors Major Product Offerings
7.3.4 F.Hoffman-La Roche Ltd. Anaplastic Lymphoma Kinase Inhibitors Sales and Revenue in Global (2017-2022)
7.3.5 F.Hoffman-La Roche Ltd. Key News
7.4 Helsinn Therapeutics
7.4.1 Helsinn Therapeutics Corporate Summary
7.4.2 Helsinn Therapeutics Business Overview
7.4.3 Helsinn Therapeutics Anaplastic Lymphoma Kinase Inhibitors Major Product Offerings
7.4.4 Helsinn Therapeutics Anaplastic Lymphoma Kinase Inhibitors Sales and Revenue in Global (2017-2022)
7.4.5 Helsinn Therapeutics Key News
7.5 Novartis AG.
7.5.1 Novartis AG. Corporate Summary
7.5.2 Novartis AG. Business Overview
7.5.3 Novartis AG. Anaplastic Lymphoma Kinase Inhibitors Major Product Offerings
7.5.4 Novartis AG. Anaplastic Lymphoma Kinase Inhibitors Sales and Revenue in Global (2017-2022)
7.5.5 Novartis AG. Key News
7.6 Oncoethix GmbH
7.6.1 Oncoethix GmbH Corporate Summary
7.6.2 Oncoethix GmbH Business Overview
7.6.3 Oncoethix GmbH Anaplastic Lymphoma Kinase Inhibitors Major Product Offerings
7.6.4 Oncoethix GmbH Anaplastic Lymphoma Kinase Inhibitors Sales and Revenue in Global (2017-2022)
7.6.5 Oncoethix GmbH Key News
7.7 Pfizer, Inc.
7.7.1 Pfizer, Inc. Corporate Summary
7.7.2 Pfizer, Inc. Business Overview
7.7.3 Pfizer, Inc. Anaplastic Lymphoma Kinase Inhibitors Major Product Offerings
7.7.4 Pfizer, Inc. Anaplastic Lymphoma Kinase Inhibitors Sales and Revenue in Global (2017-2022)
7.7.5 Pfizer, Inc. Key News
7.8 Takeda Pharmaceutical Co., Ltd.
7.8.1 Takeda Pharmaceutical Co., Ltd. Corporate Summary
7.8.2 Takeda Pharmaceutical Co., Ltd. Business Overview
7.8.3 Takeda Pharmaceutical Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Major Product Offerings
7.8.4 Takeda Pharmaceutical Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Sales and Revenue in Global (2017-2022)
7.8.5 Takeda Pharmaceutical Co., Ltd. Key News
7.9 Xcovery Holding Company, LLC
7.9.1 Xcovery Holding Company, LLC Corporate Summary
7.9.2 Xcovery Holding Company, LLC Business Overview
7.9.3 Xcovery Holding Company, LLC Anaplastic Lymphoma Kinase Inhibitors Major Product Offerings
7.9.4 Xcovery Holding Company, LLC Anaplastic Lymphoma Kinase Inhibitors Sales and Revenue in Global (2017-2022)
7.9.5 Xcovery Holding Company, LLC Key News
7.10 Tesaro, Inc.
7.10.1 Tesaro, Inc. Corporate Summary
7.10.2 Tesaro, Inc. Business Overview
7.10.3 Tesaro, Inc. Anaplastic Lymphoma Kinase Inhibitors Major Product Offerings
7.10.4 Tesaro, Inc. Anaplastic Lymphoma Kinase Inhibitors Sales and Revenue in Global (2017-2022)
7.10.5 Tesaro, Inc. Key News
8 Global Anaplastic Lymphoma Kinase Inhibitors Production Capacity, Analysis
8.1 Global Anaplastic Lymphoma Kinase Inhibitors Production Capacity, 2017-2028
8.2 Anaplastic Lymphoma Kinase Inhibitors Production Capacity of Key Manufacturers in Global Market
8.3 Global Anaplastic Lymphoma Kinase Inhibitors Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Anaplastic Lymphoma Kinase Inhibitors Supply Chain Analysis
10.1 Anaplastic Lymphoma Kinase Inhibitors Industry Value Chain
10.2 Anaplastic Lymphoma Kinase Inhibitors Upstream Market
10.3 Anaplastic Lymphoma Kinase Inhibitors Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Anaplastic Lymphoma Kinase Inhibitors Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
Research Methodology:
Anaplastic Lymphoma Kinase Inhibitors Market Size Estimation
To estimate market size and trends, we use a combination of top-down and bottom-up methods. This allows us to evaluate the market from various perspectives—by company, region, product type, and end users.
Our estimates are based on actual sales data, excluding any discounts. Segment breakdowns and market shares are calculated using weighted averages based on usage rates and average prices. Regional insights are determined by how widely a product or service is adopted in each area.
Key companies are identified through secondary sources like industry reports and company filings. We then verify revenue estimates and other key data points through primary research, including interviews with industry experts, company executives, and decision-makers.
We take into account all relevant factors that could influence the market and validate our findings with real-world input. Our final insights combine both qualitative and quantitative data to provide a well-rounded view. Please note, these estimates do not account for unexpected changes such as inflation, economic downturns, or policy shifts.
Data Source
Secondary Sources
This study draws on a wide range of secondary sources, including press releases, annual reports, non-profit organizations, industry associations, government agencies, and customs data. We also referred to reputable databases and directories such as Bloomberg, Wind Info, Hoovers, Factiva, Trading Economics, Statista, and others. Additional references include investor presentations, company filings (e.g., SEC), economic data, and documents from regulatory and industry bodies.
These sources were used to gather technical and market-focused insights, identify key players, analyze market segmentation and classification, and track major trends and developments across industries.
| Market Size |
|
|
| Market Position of Top Company |
|
|
| Qualitative Analysis |
|
|
Primary Sources
As part of our primary research, we interviewed a variety of stakeholders from both the supply and demand sides to gather valuable qualitative and quantitative insights.
On the supply side, we spoke with product manufacturers, competitors, industry experts, research institutions, distributors, traders, and raw material suppliers. On the demand side, we engaged with business leaders, marketing and sales heads, technology and innovation directors, supply chain executives, and end users across key organizations.
These conversations helped us better understand market segmentation, pricing, applications, leading players, supply chains, demand trends, industry outlook, and key market dynamics—including risks, opportunities, barriers, and strategic developments.
Key Data Information from Primary Sources
| Primary Sources | Parameters | Key Data |
| Market Segments(by Application, by Type) |
|
|
| Total Market |
|
|